• No results found

[PDF] Top 20 Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells

Has 10000 "Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells" found on our website. Below are the top 20 most common "Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells".

Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells

Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells

... PLA. Sorafenib (Cat No S7397) and TCS (Cat No S4541) were purchased from Selleck Corpora- tion (Houston, TX, ...and sorafenib were dissolved separately in DMSO (Sigma Aldrich ... See full document

10

Synergistic antitumor effects of tanshinone IIA and sorafenib or its derivative SC-1 in hepatocellular carcinoma cells

Synergistic antitumor effects of tanshinone IIA and sorafenib or its derivative SC-1 in hepatocellular carcinoma cells

... with sorafenib/SC-1 caused more potent inhibi- tion of cell migration and invasion than either agent ...HCC cells in response to these combina- tion ... See full document

9

<p>ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance</p>

<p>ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance</p>

... HCC cells were treated with 1 μ mol/L sorafenib for 12 ...the cells were harvested at indicated time ...HCC cells were injected into nude mice to form subcutaneous tumors. Sorafenib ... See full document

12

&lt;p&gt;Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells&lt;/p&gt;

<p>Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells</p>

... to sorafenib. 10 Secondly, those who are sensitive to sorafenib are likely to become tolerant to the drug as the treatment ...(eg, sorafenib: 800 ... See full document

13

Original Article The efficacy and safety of LDF, a Chinese herbal formula, compared with sorafenib for the treatment of advanced hepatocellular carcinoma in Chinese patients: a retrospective cohort study

Original Article The efficacy and safety of LDF, a Chinese herbal formula, compared with sorafenib for the treatment of advanced hepatocellular carcinoma in Chinese patients: a retrospective cohort study

... the effect of tonifying Qi and invigorating the circulation of blood in the deficiency of vital energy and blood ...the effect of cancer treat- ment ...the antitumor activity by promoting the ... See full document

8

Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma

Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma

... anticancer effect of RO3306 and sorafenib on liver CSC ...sphere cells were treated with DMSO, RO3306 (4 mM), sorafenib (5 mM), and RO3306 (4 mM) combined with sorafenib (5 ...RO3306, ... See full document

14

Original Article Trans-arterial chemoembolization with sorafenib treatment improves long-term overall survival of patients with intermediate hepatocellular carcinoma

Original Article Trans-arterial chemoembolization with sorafenib treatment improves long-term overall survival of patients with intermediate hepatocellular carcinoma

... TACE treatment can cause hypoxia in tumor cells and surrounding tissues, increase expres- sion of vascular endothelial growth factor (VEGF) by upregulating hypoxia-inducible fac- tors, stimulate the growth ... See full document

10

Emerging agents and regimens for hepatocellular carcinoma

Emerging agents and regimens for hepatocellular carcinoma

... cell carcinoma by ...in sorafenib- treated patients with advanced HCC ...anti-tumor effect than nivolumab monotherapy with a higher ORR (31% vs 14%) [48, 65], the median DOR was 17 months, and the ... See full document

10

Ardelt, Maximilian
  

(2018):


	Sorafenib response in hepatocellular carcinoma therapy: introducing new possibilities with Cdk5 inhibition.


Dissertation, LMU München: Fakultät für Chemie und Pharmazie

Ardelt, Maximilian (2018): Sorafenib response in hepatocellular carcinoma therapy: introducing new possibilities with Cdk5 inhibition. Dissertation, LMU München: Fakultät für Chemie und Pharmazie

... knockdown cells displayed a significant upregulation of p62/Sequestosome1 as shown by proteomic analysis and western blot analysis (Figure 14 and Figure 18a, ...shRNA cells was increased in response to ... See full document

100

Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma

Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma

... vivo antitumor effects with the mechanisms identified in vitro, intratumoral biomarkers were assessed by immunohistochemical ...the hepatocellular carcinoma tumor xenografts for the potential ... See full document

17

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma

... Abstract: Hepatocellular carcinoma (HCC) is frequently diagnosed in the setting of chronic liver disease and ...The treatment options that may offer cure are either resection or liver ...either ... See full document

7

SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma

SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma

... The analysis of gene-to-gene connection using the Liver hepatocellular carcinoma data in c-BioPortal (http://www.cbioportal.org/public-portal/) showed the association of SLC15A2 with cystic fibrosis ... See full document

12

&lt;p&gt;Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma:A Propensity Score Matching Analysis&lt;/p&gt;

<p>Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma:A Propensity Score Matching Analysis</p>

... During the whole course of this study, different kinds of adverse events (AEs) appeared in two cohorts and symp- tomatic treatments were adopted to alleviate patients ’ symptoms. All AEs are listed and their incidences ... See full document

10

Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus

Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus

... optimal treatment strategy for HCC with ...of treatment with TACE or TACE–sorafenib, and they finally decided the choice of treat- ...TACE treatment and were diagnosed with disease progression ... See full document

8

Cancer and liver cirrhosis: implications on prognosis and management

Cancer and liver cirrhosis: implications on prognosis and management

... In gastric cancer, liver cirrhosis was an independent risk factor for postdischarge morbidity after radical gas- trectomy 193 and patients with more advanced (Child-Pugh B-C) cirrhosis had a signi fi cantly higher ... See full document

16

Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions

Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions

... with sorafenib intolerance or resis- tance are unable to to receive additional therapy because of the advanced nature of their disease and cirrhosis, those with a good performance status often seek additional ... See full document

8

Objective Response by mRECIST is an Independent Prognostic Factor for overall Survival in Hepatocellular Carcinoma in SILIUS Trial

Objective Response by mRECIST is an Independent Prognostic Factor for overall Survival in Hepatocellular Carcinoma in SILIUS Trial

... versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority ...al. Sorafenib in advanced hepatocellular ... See full document

27

Silencing  the expression of copine-III enhances the sensitivity of hepatocellular carcinoma cells to the molecular targeted agent sorafenib

Silencing the expression of copine-III enhances the sensitivity of hepatocellular carcinoma cells to the molecular targeted agent sorafenib

... with sorafenib treatment than the CPNE3-low group (Table 2; Figure 1C and D): the time to progress (TTP) of the CPNE3-high group of patients (median TTP: ... See full document

11

&lt;p&gt;Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities&lt;/p&gt;

<p>Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities</p>

... A wide range of nanostructures based on organic materials has been advanced for drug delivery systems. The fi rst FDA approved nanodrug was based on nanocarrier liposome which is an organic nanocarrier utilizing ... See full document

20

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

... tolerate treatment with sorafenib (400 mg bid) for at least 20 days and the reason for termination of sorafenib had to be documented disease ...of sorafenib treatment, patients had to ... See full document

6

Show all 10000 documents...